

DISEASE BURDEN



In 2023, an estimated 10.8 million people fell ill with TB worldwide. About 1.25 million people died from TB in 2023. Most of the people who fall ill with TB live in LMICs. TB is a leading cause of death from a single infectious agent - including in people with HIV- and a major cause of deaths related to antimicrobial resistance.



CLINICAL RELEVANCE



Quabodepistat is a DprE1 inhibitor being investigated for tuberculosis treatment as part of a regimen. It exhibits potent antituberculosis activity and has a favourable safety profile. Despite the premature termination of PAN-TB Consortium trials involving quabodepistatsince the trial did not support the investigational regimens in achieving the objective of identifying a new three-month tuberculosis treatment-Otsuka plans to study the drug alongside bedaquiline and delamanid in phase III trials.

INTELLECTUAL PROPERTY LANDSCAPE







SERVICE DELIVERY ENABLERS

The availability of fully-oral TB treatment regimens simplifies service delivery and improves adherence, but there remains health system requirements for diagnosis and monitoring and the implementation of directly-observed therapy (DOT). While TB treatment has shortened in recent years, it still takes several months, which is challenging for adherence. A fully oral and shorter (ideally pan-TB) regimen could be game changing.